300653 正海生物
交易中 12-29 14:18:03
资讯
新帖
简况
正海生物:钙硅生物陶瓷骨修复材料注册接近尾声
证券之星 · 12-24
正海生物:钙硅生物陶瓷骨修复材料注册接近尾声
正海生物:重组蛋白项目正稳步推进
证券之星 · 12-16
正海生物:重组蛋白项目正稳步推进
正海生物(300653)披露签订重组III型胶原蛋白技术开发合同,12月15日股价上涨0.24%
证券之星 · 12-15
正海生物(300653)披露签订重组III型胶原蛋白技术开发合同,12月15日股价上涨0.24%
正海生物(300653.SZ)与中国农科院生物所签署一项技术开发合同
智通财经 · 12-15
正海生物(300653.SZ)与中国农科院生物所签署一项技术开发合同
正海生物(300653)披露取得医疗器械注册变更文件,12月09日股价下跌1.4%
证券之星 · 12-09
正海生物(300653)披露取得医疗器械注册变更文件,12月09日股价下跌1.4%
正海生物:钙硅生物陶瓷骨修复材料预计2025年获注册证
证券之星 · 12-04
正海生物:钙硅生物陶瓷骨修复材料预计2025年获注册证
股市必读:正海生物(300653)11月17日董秘有最新回复
证券之星 · 11-18
股市必读:正海生物(300653)11月17日董秘有最新回复
正海生物:持续开展干细胞技术研究及应用
证券之星 · 11-17
正海生物:持续开展干细胞技术研究及应用
股市必读:正海生物(300653)股东户数1.59万户,较上期减少5.57%
证券之星 · 10-27
股市必读:正海生物(300653)股东户数1.59万户,较上期减少5.57%
正海生物(300653)2025年三季报简析:净利润同比下降46.1%,三费占比上升明显
证券之星 · 10-26
正海生物(300653)2025年三季报简析:净利润同比下降46.1%,三费占比上升明显
正海生物(300653.SZ)发布前三季度业绩,归母净利润6740.22万元,下降46.10%
智通财经 · 10-24
正海生物(300653.SZ)发布前三季度业绩,归母净利润6740.22万元,下降46.10%
正海生物(300653)9月30日股东户数1.59万户,较上期减少5.57%
证券之星 · 10-24
正海生物(300653)9月30日股东户数1.59万户,较上期减少5.57%
股市必读:正海生物(300653)10月16日董秘有最新回复
证券之星 · 10-17
股市必读:正海生物(300653)10月16日董秘有最新回复
正海生物:可吸收口腔膜将丰富现有产品组合
证券之星 · 10-16
正海生物:可吸收口腔膜将丰富现有产品组合
正海生物最新公告:口腔可吸收生物膜进入临床试验
证券之星 · 10-09
正海生物最新公告:口腔可吸收生物膜进入临床试验
正海生物:钙硅生物陶瓷骨修复材料预计2025年底取得注册证
证券之星 · 09-29
正海生物:钙硅生物陶瓷骨修复材料预计2025年底取得注册证
股市必读:正海生物(300653)9月17日披露最新机构调研信息
证券之星 · 09-18
股市必读:正海生物(300653)9月17日披露最新机构调研信息
正海生物:江西彼得明奇私募、湘禾投资等多家机构于9月16日调研我司
证券之星 · 09-17
正海生物:江西彼得明奇私募、湘禾投资等多家机构于9月16日调研我司
股市必读:正海生物(300653)9月12日董秘有最新回复
证券之星 · 09-15
股市必读:正海生物(300653)9月12日董秘有最新回复
正海生物:活性生物骨用于填充骨缺损
证券之星 · 09-10
正海生物:活性生物骨用于填充骨缺损
加载更多
公司概况
公司名称:
烟台正海生物科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2017-05-16
主营业务:
烟台正海生物科技股份有限公司的主营业务是生物再生材料的研发、生产与销售。公司的主要产品是口腔修复膜、可吸收硬脑(脊)膜补片、硬脑(脊)膜补片、皮肤修复膜、骨修复材料、活性生物骨、光固化复合树脂、自酸蚀粘接剂、窝沟封闭剂、磷酸酸试剂、外科用填塞海绵。公司历经20余年的发展,先后承担了国家“863计划”、国家火炬计划,是国家首批专精特新“小巨人”企业、国家知识产权示范企业、高新技术企业。
发行价格:
11.72
{"stockData":{"symbol":"300653","market":"SZ","secType":"STK","nameCN":"正海生物","latestPrice":20.05,"timestamp":1766989083000,"preClose":20.39,"halted":0,"volume":2191737,"delay":0,"changeRate":-0.0167,"floatShares":180000000,"shares":180000000,"eps":0.4277,"marketStatus":"交易中","change":-0.34,"latestTime":"12-29 14:18:03","open":20.39,"high":20.44,"low":19.97,"amount":44057100,"amplitude":0.0231,"askPrice":20.05,"askSize":17,"bidPrice":20.04,"bidSize":25,"shortable":0,"etf":0,"ttmEps":0.4277,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1766991600000},"marketStatusCode":2,"adr":0,"adjPreClose":20.39,"symbolType":"stock","openAndCloseTimeList":[[1766971800000,1766979000000],[1766984400000,1766991600000]],"highLimit":22.43,"lowLimit":18.35,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":180000000,"isCdr":false,"pbRate":4.2,"roa":"--","peRate":46.878653,"roe":"7.61%","epsLYR":0.75,"committee":0.637795,"marketValue":3609000000,"turnoverRate":0.0122,"status":1,"floatMarketCap":3609000000},"requestUrl":"/m/hq/s/300653","defaultTab":"news","newsList":[{"id":"2593423076","title":"正海生物:钙硅生物陶瓷骨修复材料注册接近尾声","url":"https://stock-news.laohu8.com/highlight/detail?id=2593423076","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593423076?lang=zh_cn&edition=full","pubTime":"2025-12-24 11:37","pubTimestamp":1766547433,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物12月23日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,贵公司原本预计钙硅生物陶瓷骨修复材料预计于2025年内取得注册证,年内能达成吗?公司钙硅生物陶瓷骨修复材料产品注册工作已接近尾声,公司将持续跟进产品注册进展并及时履行信披义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400014660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300653","BK0046"],"gpt_icon":0},{"id":"2591109602","title":"正海生物:重组蛋白项目正稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2591109602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591109602?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:39","pubTimestamp":1765874356,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物12月16日在投资者关系平台上答复投资者关心的问题。公司与江苏集萃研究所合作开展的“重组生物活性蛋白产品的研究开发”项目正稳步推进中,不存在终止合作的情形。两项合作开发项目具有不同的研发方向及技术路径,都是公司为丰富产品矩阵、提升长期竞争力的战略举措。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600025191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2591642159","title":"正海生物(300653)披露签订重组III型胶原蛋白技术开发合同,12月15日股价上涨0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642159?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:29","pubTimestamp":1765808949,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘,正海生物报收于20.68元,较前一交易日上涨0.24%,最新总市值为37.22亿元。该股当日开盘20.6元,最高20.9元,最低20.24元,成交额达4004万元,换手率为1.08%。公司近日发布公告称,烟台正海生物科技股份有限公司与中国农业科学院生物技术研究所签署关于‘重组III型胶原蛋白产品的研究开发’项目的《技术开发合同》,合同总金额为1,200万元,将按里程碑节点分期支付。项目研究成果及知识产权由双方共有,甲方享有独占使用权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500036019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2591619376","title":"正海生物(300653.SZ)与中国农科院生物所签署一项技术开发合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2591619376","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591619376?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:22","pubTimestamp":1765786939,"startTime":"0","endTime":"0","summary":"智通财经APP讯,正海生物(300653.SZ)公告,公司近日与受托方中国农业科学院生物技术研究所(简称“中国农科院生物所”)签署了关于“重组III型胶原蛋白产品的研究开发”项目的《技术开发合同》。合同总金额为1200万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2590342820","title":"正海生物(300653)披露取得医疗器械注册变更文件,12月09日股价下跌1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590342820","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590342820?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:21","pubTimestamp":1765290113,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘,正海生物报收于21.1元,较前一交易日下跌1.4%,最新总市值为37.98亿元。该股当日开盘21.37元,最高21.49元,最低21.05元,成交额达6885.58万元,换手率为1.8%。公司于近日发布公告称,烟台正海生物科技股份有限公司于近日取得国家药品监督管理局颁发的《医疗器械变更注册(备案)文件》,完成产品“皮肤修复膜”的规格型号及产品技术要求的变更。上述变更文件需与原注册证共同使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900040821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09997","BK1222","BK1583","BK0046","09996","BK1100","159883","BK1574","BK0251","300653"],"gpt_icon":0},{"id":"2588863006","title":"正海生物:钙硅生物陶瓷骨修复材料预计2025年获注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2588863006","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588863006?lang=zh_cn&edition=full","pubTime":"2025-12-04 15:03","pubTimestamp":1764831795,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)12月04日在投资者关系平台上答复投资者关心的问题。投资者提问:请问董秘!11月14日在印度尼西亚举行的牙科展览会上正海生物受邀参会,携海奥口腔修复膜、海奥3D钙硅生物陶瓷骨修复材料在I04展位与业界同仁进行深入交!海奥3D钙硅生物陶瓷骨修复材已经通过注册了吗?正海生物回复:您好!钙硅生物陶瓷骨修复材料预计于2025年内取得注册证,后续进展公司将及时履行信披义务。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400017706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0251","BK0046"],"gpt_icon":0},{"id":"2584675222","title":"股市必读:正海生物(300653)11月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584675222","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584675222?lang=zh_cn&edition=full","pubTime":"2025-11-18 02:44","pubTimestamp":1763405054,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘,正海生物报收于20.91元,下跌1.41%,换手率1.44%,成交量2.58万手,成交额5400.79万元。董秘最新回复投资者: 建议公司可以考虑凭借皮肤膜切入人形机器人的人工皮肤赛道,该赛道与公司现有业务基础契合且高景气度。交易信息汇总资金流向11月17日主力资金净流出546.64万元;游资资金净流出501.35万元;散户资金净流入1047.99万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800001684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0251","300653"],"gpt_icon":0},{"id":"2584612491","title":"正海生物:持续开展干细胞技术研究及应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2584612491","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584612491?lang=zh_cn&edition=full","pubTime":"2025-11-17 15:06","pubTimestamp":1763363184,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)11月17日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司对于干细胞的研究怎么样,有什么成果,公司对于未来发展有什么预期。正海生物回复:您好!公司始终将干细胞技术的研究及应用作为重要战略布局,近年来持续开展相关研究工作,未来公司也将继续保持对干细胞领域的跟踪与研究,探索相关技术实现产业化的更多可能性。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700013779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2578685526","title":"股市必读:正海生物(300653)股东户数1.59万户,较上期减少5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578685526","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578685526?lang=zh_cn&edition=full","pubTime":"2025-10-27 06:07","pubTimestamp":1761516436,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,正海生物报收于19.93元,上涨0.66%,换手率0.86%,成交量1.54万手,成交额3075.65万元。来自股本股东变化:截至2025年9月30日股东户数环比下降5.57%,户均持股数量上升至1.13万股,筹码集中度提升。交易信息汇总资金流向10月24日主力资金净流入119.78万元;游资资金净流入179.39万元;散户资金净流出299.18万元。股本股东变化股东户数变动近日正海生物披露,截至2025年9月30日公司股东户数为1.59万户,较6月30日减少937.0户,减幅为5.57%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700001719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"gpt_icon":0},{"id":"2578832486","title":"正海生物(300653)2025年三季报简析:净利润同比下降46.1%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2578832486","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578832486?lang=zh_cn&edition=full","pubTime":"2025-10-26 06:15","pubTimestamp":1761430554,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期正海生物发布2025年三季报。截至本报告期末,公司营业总收入2.76亿元,同比下降5.36%,归母净利润6740.22万元,同比下降46.1%。按单季度数据看,第三季度营业总收入8787.71万元,同比下降5.84%,第三季度归母净利润2091.65万元,同比下降46.4%。本报告期正海生物三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达37.23%。去年的净利率为37.07%,算上全部成本后,公司产品或服务的附加值极高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600002241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653"],"gpt_icon":0},{"id":"2577591211","title":"正海生物(300653.SZ)发布前三季度业绩,归母净利润6740.22万元,下降46.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577591211","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577591211?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:46","pubTimestamp":1761299160,"startTime":"0","endTime":"0","summary":"智通财经APP讯,正海生物(300653.SZ)发布2025年三季度报告,该公司前三季度营业收入为2.76亿元,同比减少5.36%。归属于上市公司股东的净利润为6740.22万元,同比减少46.10%。归属于上市公司股东的扣除非经常性损益的净利润为5918.16万元,同比减少45.34%。基本每股收益为0.37元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"正海生物(300653.SZ)发布前三季度业绩,归母净利润6740.22万元,下降46.10%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300653"],"gpt_icon":0},{"id":"2577599635","title":"正海生物(300653)9月30日股东户数1.59万户,较上期减少5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577599635","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577599635?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:16","pubTimestamp":1761297402,"startTime":"0","endTime":"0","summary":"证券之星消息,近日正海生物披露,截至2025年9月30日公司股东户数为1.59万户,较6月30日减少937.0户,减幅为5.57%。在医疗器械行业个股中,正海生物股东户数低于行业平均水平,截至9月30日,医疗器械行业平均股东户数为2.15万户。从股价来看,2025年6月30日至2025年9月30日,正海生物区间跌幅为2.83%,在此期间股东户数减少937.0户,减幅为5.57%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400030686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2576200547","title":"股市必读:正海生物(300653)10月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2576200547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576200547?lang=zh_cn&edition=full","pubTime":"2025-10-17 03:46","pubTimestamp":1760643970,"startTime":"0","endTime":"0","summary":"截至2025年10月16日收盘,正海生物报收于19.91元,下跌0.4%,换手率0.77%,成交量1.38万手,成交额2750.31万元。董秘最新回复投资者: 请问董秘!公司目前暂无相关合作。请公司抓紧时间推动有市场竞争力的产品董秘: 您好!公司可吸收口腔膜将丰富现有口腔膜产品组合,能够精准匹配口腔种植领域相关适应症的临床修复需求,符合公司的长远发展战略。当日关注点来自交易信息汇总:10月16日主力资金净流入193.21万元,显示主力对个股呈积极介入态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700004049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2575749475","title":"正海生物:可吸收口腔膜将丰富现有产品组合","url":"https://stock-news.laohu8.com/highlight/detail?id=2575749475","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575749475?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:52","pubTimestamp":1760619147,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)10月16日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司新开展临床的可吸收口腔膜和公司现有的一二代口腔膜有什么区别?功能上在哪里有互补?为什么不抓紧推动宫腔修复膜的注册和人脐带干细胞的临床?请公司抓紧时间推动有市场竞争力的产品正海生物回复:您好!公司可吸收口腔膜将丰富现有口腔膜产品组合,能够精准匹配口腔种植领域相关适应症的临床修复需求,符合公司的长远发展战略。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101600035693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300653","BK0251"],"gpt_icon":0},{"id":"2574377821","title":"正海生物最新公告:口腔可吸收生物膜进入临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2574377821","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574377821?lang=zh_cn&edition=full","pubTime":"2025-10-09 17:23","pubTimestamp":1760001822,"startTime":"0","endTime":"0","summary":"正海生物(300653.SZ)公告称,公司研发的口腔可吸收生物膜已完成首例受试者随机入组,正式进入临床试验。该产品为第三类医疗器械,适用于口腔牙缺失需种植修复时起物理阻隔作用,防止充填材料移动,以及拔牙后、残根拔除术后拔牙窝填充等。临床试验的开展预计不会对公司现有业务和经营业绩产生确定性影响,后续进展公司将及时履行信息披露义务。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900022330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"gpt_icon":0},{"id":"2571772848","title":"正海生物:钙硅生物陶瓷骨修复材料预计2025年底取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2571772848","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571772848?lang=zh_cn&edition=full","pubTime":"2025-09-29 11:33","pubTimestamp":1759116787,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)09月28日在投资者关系平台上答复投资者关心的问题。投资者提问:请问董秘!钙硅生物陶瓷骨修复材料审批进展如何?最快多长时间能够拿到注册证?正海生物回复:您好!钙硅生物陶瓷骨修复材料预计于2025年底取得注册证。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900010133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300653","BK0046"],"gpt_icon":0},{"id":"2568414756","title":"股市必读:正海生物(300653)9月17日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2568414756","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568414756?lang=zh_cn&edition=full","pubTime":"2025-09-18 04:26","pubTimestamp":1758140772,"startTime":"0","endTime":"0","summary":"截至2025年9月17日收盘,正海生物报收于20.73元,下跌0.48%,换手率1.13%,成交量2.03万手,成交额4216.81万元。来自机构调研要点:人脐带间充质干细胞项目处于产品工艺验证阶段,将拓展宫腔软组织修复领域布局。答:活性生物骨是国内首个含与胶原特异结合的rhBMP-2的骨填充产品,具有很高的创新性。答:截至目前,已有6个省级和2个省际联盟开展了脑膜产品的带量采购,覆盖省份合计达24个省。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091800003144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300653","BK0046"],"gpt_icon":0},{"id":"2568456167","title":"正海生物:江西彼得明奇私募、湘禾投资等多家机构于9月16日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2568456167","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568456167?lang=zh_cn&edition=full","pubTime":"2025-09-17 11:01","pubTimestamp":1758078099,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年9月17日正海生物发布公告称江西彼得明奇私募康健、湘禾投资杨杨、首创证券刘琳、中金公司朱言音 刘雅馨于2025年9月16日调研我司。正海生物主营业务:生物再生材料的研发、生产与销售,搭建涵盖研发、临床、注册、生产、质保、销售全链条的业务平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700015218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0251","BK0046"],"gpt_icon":0},{"id":"2567118157","title":"股市必读:正海生物(300653)9月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2567118157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567118157?lang=zh_cn&edition=full","pubTime":"2025-09-15 03:46","pubTimestamp":1757879176,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘,正海生物报收于20.98元,上涨1.6%,换手率2.0%,成交量3.6万手,成交额7527.7万元。董秘最新回复投资者: 浙大研究的骨胶水,你们公司有相关研究吗?是不是可以考虑收购协同发展?请公司关注一下董秘: 您好!公司尚未开展相关产品研究,感谢您对公司的关注与建议!当日关注点来自交易信息汇总:9月12日主力资金净流入575.44万元,显示主力对个股短期关注度提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500001165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300653","BK0251"],"gpt_icon":0},{"id":"2566647678","title":"正海生物:活性生物骨用于填充骨缺损","url":"https://stock-news.laohu8.com/highlight/detail?id=2566647678","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566647678?lang=zh_cn&edition=full","pubTime":"2025-09-10 08:45","pubTimestamp":1757465114,"startTime":"0","endTime":"0","summary":"证券之星消息,正海生物(300653)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问:请问董秘!公司的产品海昱活性生物骨对股骨头坏死有没有作用?正海生物回复:您好!活性生物骨用于填充由于创伤或手术造成的、不影响骨结构稳定性的骨缺损。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091000006908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0251","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766989114153,"stockEarnings":[{"period":"1week","weight":-0.0164},{"period":"1month","weight":-0.0516},{"period":"3month","weight":0.0324},{"period":"6month","weight":0.0139},{"period":"1year","weight":-0.0459},{"period":"ytd","weight":-0.0204}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台正海生物科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"15878人(较上一季度减少5.57%)","perCapita":"11336股","listingDate":"2017-05-16","address":"山东省烟台市福山区经济技术开发区南京大街7号","registeredCapital":"18000万元","survey":" 烟台正海生物科技股份有限公司的主营业务是生物再生材料的研发、生产与销售。公司的主要产品是口腔修复膜、可吸收硬脑(脊)膜补片、硬脑(脊)膜补片、皮肤修复膜、骨修复材料、活性生物骨、光固化复合树脂、自酸蚀粘接剂、窝沟封闭剂、磷酸酸试剂、外科用填塞海绵。公司历经20余年的发展,先后承担了国家“863计划”、国家火炬计划,是国家首批专精特新“小巨人”企业、国家知识产权示范企业、高新技术企业。","listedPrice":11.72},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"正海生物(300653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供正海生物(300653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"正海生物,300653,正海生物股票,正海生物股票老虎,正海生物股票老虎国际,正海生物行情,正海生物股票行情,正海生物股价,正海生物股市,正海生物股票价格,正海生物股票交易,正海生物股票购买,正海生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"正海生物(300653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供正海生物(300653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}